Medical expert of the article
New publications
Preparations
Vigamox
Last reviewed: 10.08.2022
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Vigamox is an antimicrobial drug with bactericidal activity; belongs to the category of fluoroquinolones.
The drug demonstrates a therapeutic effect on a wide range of bacteria: gram-positive and -negative, and in addition to this acid-fast and atypical microbes along with anaerobes: mycoplasma, chlamydia, legionella. At the same time, it affects microbial strains that are resistant to macrolides and β-lactam antibiotics. [1]
Indications Vigamox
It is used in the local therapy of conjunctivitis associated with bacteria showing sensitivity to moxifloxacin.
Release form
The release is realized in the form of eye drops - inside bottles with a capacity of 3 or 5 ml.
Pharmacodynamics
The effect of the drug develops in relation to such categories of pathogenic microbes:
- gram-positive - pyogenic streptococci (subgroup A), Staphylococcus aureus (among them colonies that are resistant to methicillin) and pneumococci (this includes colonies resistant to penicillin with macrolides);
- gram-negative - moraxella catarrhalis, Klebsiella pneumoniae, Haemophilus influenzae with Escherichia coli, Haemophilus parainfluenzae and enterobacter cloaca;
- atypical - chlamydia pneumonia or mycoplasma pneumonia.
The bacteria listed below have shown sensitivity to moxifloxacin during in vitro tests, but the therapeutic effect and safety in the treatment of such infections have not been confirmed. Among these pathogens:
- gram-positive elements: among those streptococci are agalactia, Staphylococcus hominis, epidermal staphylococci (this includes colonies showing sensitivity to methicillin), Streptococcus milleri, saprophytic staphylococci, St. Cohnii, streptococcus mitis, Streptococcus dysgalactiae and St. Haemolyticus. In addition, there are also vulgar proteas with mirabilis proteas, and with it the Providences of Röttger or Stewart, Enterobacter sakazaki, Enterobacter aerogenes, Morgan bacteria, Enterobacter agglomerans and Enterobacter Intermedius;
- gram-negative bacteria: Klebsiella oxytoca and whooping cough;
- anaerobes: B.eggerthii, Bacteroides ovatus with Fragilis bacteroids, Bacteroides distasonis with tetayotaomycron bacteria, B.uniformis with perfringens clostridia, propionibacteria, P.asaccharolyticus, Porphyromonas spp., Fusobacterium and Porphyromonus anerophyllus and aerophy precursus, aerophy Ramosum;
- atypical elements: legionella pneumophila and Caxiella burnettii.
The effect of moxifloxacin is determined by its parameters inside the blood with tissues. The minimum effective bactericidal values are almost the same as the minimum inhibitory level. [2]
The principles of resistance development, which inactivate penicillins, aminoglycosides with cephalosporins, and at the same time tetracyclines with macrolides, do not affect the antibacterial efficacy of moxifloxacin. Cross-resistance does not develop in these drug categories and moxifloxacin. At the same time, there is no plasmid-mediated way of emergence of resistance. The incidence of resistance to moxifloxacin is relatively low. [3]
In vitro tests have shown that a number of successively developing mutations cause a slow development of resistance against Vigamox. With repeated exposure to bacteria, moxifloxacin (in subminimal inhibitory values) insignificantly increases the level of MIC.
Cross-resistance is observed with substances from the fluoroquinolone subgroup, but at the same time, individual anaerobes and gram-positive elements resistant to other fluoroquinolones continue to demonstrate sensitivity to moxifloxacin.
Dosing and administration
The medication must be instilled inside the eyes for 4 days, in the amount of 1 drop, 3 times a day. Do not touch the open tip with any foreign objects, as this can lead to bacterial contamination of the liquid.
The use of drugs in pediatrics is absolutely safe and highly effective, so it can be used without restrictions in dosages similar to those for adults.
Use Vigamox during pregnancy
The medication is prescribed exclusively for vital indications, in the absence of a result from the use of drugs from other groups.
Contraindications
It is contraindicated to use the medication in case of severe intolerance caused by its active or auxiliary elements.
Side effects Vigamox
From local side symptoms: itching, keratitis, dryness of the ocular mucosa, visual fogging, temporary discomfort and subconjunctival bleeding.
Occasionally, general manifestations occur: pharyngitis, headaches, respiratory failure, loss of consciousness and Quincke's edema.
Storage conditions
Vigamox must be stored inside a closed bottle at temperatures in the range of 20-25 ° C.
Shelf life
Vigamox is allowed to be used for a 36-month term from the date of the release of the pharmaceutical product. The shelf life of an opened bottle is 1 month.
Analogs
An analogue of drugs is Avelox.
Attention!
To simplify the perception of information, this instruction for use of the drug "Vigamox" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.